Showing 30 of 4110 posts
Anglo American completes landmark Codelco deal to unlock 2.7mt of additional low-cost copper production from 2030.
JoshuaJune 24, 2026
Berkeley Group FY26 results show resilient cash flow and bigger share buybacks despite 14.7% profit drop.
JoshuaJune 24, 2026
Avingtrans delivers steady profits, major nuclear & infrastructure contract wins, but faces a £5m US Covid loan repayment issue.
JoshuaJune 24, 2026
Built Cybernetics' recurring revenue jumps 37% despite a headline revenue dip, as the property tech group transitions from project work to software income.
JoshuaJune 24, 2026
Liontrust profits fell sharply but net outflows slowed and River Global acquisition nears completion, signalling a potential recovery.
JoshuaJune 24, 2026
Cavendish FY26 results: revenue up, dividend held, but profits and EPS slipped amid UK small-cap market headwinds.
JoshuaJune 24, 2026
Vertu Motors AGM update reveals like-for-like growth across all channels and higher aftersales profits, guiding FY27 ahead of market expectations.
JoshuaJune 24, 2026
ProCook FY26 results: record revenue, 23% growth, higher margins, new customers and strong cash generation.
JoshuaJune 24, 2026
THG reports H1 revenue up 6.5%, Adjusted EBITDA nearly doubling, and strongest free cash flow since 2021. Full-year guidance reaffirmed.
JoshuaJune 24, 2026
Schroder European REIT proposes managed wind-down to close stubborn share price discount, aiming to sell assets over 2-3 years and return cash to investors.
JoshuaJune 24, 2026
Thalia Therapeutics acquires Sanmirna and raises £2.75M for Phase 1 AML therapy, adding clinical-stage RNA asset with 2027 data catalyst.
JoshuaJune 24, 2026
Beximco Pharma profit up 34% in nine months, driven by strong domestic sales, margin growth and lower borrowing costs.
JoshuaJune 24, 2026
JEGI delivers 20.1% NAV return, beats benchmark by 5.3%. Dividend rises to 5.0p, with proposed EOT rollover deal to boost scale and liquidity.
JoshuaJune 23, 2026
Resilient FY26 results from Intercede: revenue dip offset by £20m cash, rising recurring income & strong early FY27 order momentum.
JoshuaJune 23, 2026
Bunzl upgrades 2026 revenue guidance after strong first-half trading, with North America recovery and new bolt-on acquisition in Australia.
JoshuaJune 23, 2026
Angus Energy reports 30% production uplift at Saltfleetby, strong cash generation but warns on going concern ahead of restructuring.
JoshuaJune 23, 2026
EnSilica reports record FY26 revenue of £27.5m and rising profits, with strong FY27 guidance and 80% revenue already secured.
JoshuaJune 23, 2026
Telecom Plus delivers strong FY26 results but unveils FY27 profit dip as it invests £55m annually to double multiservice customers by FY31.
JoshuaJune 23, 2026
Turnaround story: profit & cash surge at Dialight despite revenue decline, debt slashed and margins improving.
JoshuaJune 23, 2026
IDS delivers robust FY26 revenue growth, but profit falls 20% - parcel and locker progress offset by cost pressure.
JoshuaJune 23, 2026
Iomart FY2026 results: revenue up but organic decline, churn beats bookings, margins fall. A transition year with cautious outlook for FY27.
JoshuaJune 23, 2026
Severfield’s FY26 results: revenue steady, profits dip, and a transition year ahead as refreshed strategy targets margin recovery.
JoshuaJune 23, 2026
Arkle Resources pivots to uranium in Namibia post year-end, sharpening its energy metals focus and giving investors a clearer, higher-risk exploration story.
JoshuaJune 23, 2026
Triad Group reports strong FY2026: revenue up 16%, profit before tax up 27%, dividend raised to 9p. Cash strengthens with £4.2m. Major contract wins.
JoshuaJune 22, 2026
eEnergy H1 revenue jumps to £22m, but FY26 EBITDA guidance slashed to £1.7m after pipeline review. Cost cuts of £2m aim to protect profits.
JoshuaJune 22, 2026
NextEnergy Solar Fund full year results: NAV drops to 76.1p, dividend reset to 4.5-5.1p, and strategic asset sales target lower gearing.
JoshuaJune 22, 2026
Transense Technologies: FY26 revenue and EBITDA miss expectations, but SAWsense growth and Bridgestone royalties offer stability. FY27 outlook prudent, not a collapse.
JoshuaJune 22, 2026
ValiRx 2025 results show cost cuts and pipeline progress, but a going concern warning highlights funding risks investors can't ignore.
JoshuaJune 22, 2026
Babcock's FY26 results show solid revenue and cash growth with increased dividends, yet a £140m Type 31 charge masks underlying strength in defence and nuclear.
JoshuaJune 22, 2026
CelLBxHealth FY2025: revenue slumped to £1.4m, but cost cuts and partnerships with AstraZeneca, Roche, and QIAGEN aim for 50% growth in FY2026. High risk, strategic reset.
JoshuaJune 22, 2026